The release is primarily for Japan but breifly;
1. RIKEN and REGiMMUNE has developed recombinant cedar antigen for treatment of cedar allergy. Because of its unique conformation, it has lower or no risk of anaphylactic shock which is expected for native antige used for desensitization therapy.
2. Animal studies have been conducted and efficacy and safety was confirmed
3. RIKEN and REGiMMUNE are starting production and preclinical studies to be prepared for clinical trial
4. Cedar antigen is well know allergy causing allergen and 13-16% of Japanese are affected